- Home
- NERV vs AIMD Comparison
NERV vs AIMD Comparison
Compare NERV & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NERV
- AIMD
- Stock Information
- Founded
- NERV 2007
- AIMD 1984
- Country
- NERV United States
- AIMD United States
- Employees
- NERV N/A
- AIMD N/A
- Industry
- NERV Biotechnology: Pharmaceutical Preparations
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- NERV Health Care
- AIMD Health Care
- Exchange
- NERV Nasdaq
- AIMD Nasdaq
- Market Cap
- NERV 14.6M
- AIMD 16.9M
- IPO Year
- NERV 2014
- AIMD N/A
- Fundamental
- Price
- NERV $4.78
- AIMD $3.62
- Analyst Decision
- NERV Hold
- AIMD
- Analyst Count
- NERV 1
- AIMD 0
- Target Price
- NERV $5.00
- AIMD N/A
- AVG Volume (30 Days)
- NERV 9.3M
- AIMD 64.2K
- Earning Date
- NERV 11-05-2025
- AIMD 11-14-2025
- Dividend Yield
- NERV N/A
- AIMD N/A
- EPS Growth
- NERV N/A
- AIMD N/A
- EPS
- NERV 1.48
- AIMD N/A
- Revenue
- NERV N/A
- AIMD $110,870.00
- Revenue This Year
- NERV N/A
- AIMD N/A
- Revenue Next Year
- NERV N/A
- AIMD N/A
- P/E Ratio
- NERV $3.06
- AIMD N/A
- Revenue Growth
- NERV N/A
- AIMD 70.25
- 52 Week Low
- NERV $1.15
- AIMD $2.00
- 52 Week High
- NERV $12.46
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- NERV 63.84
- AIMD 46.66
- Support Level
- NERV $4.27
- AIMD $3.39
- Resistance Level
- NERV $12.46
- AIMD $3.75
- Average True Range (ATR)
- NERV 0.86
- AIMD 0.24
- MACD
- NERV 0.16
- AIMD -0.06
- Stochastic Oscillator
- NERV 24.84
- AIMD 21.90
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.